Compare Extra Space Storage, Inc. (EXR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Extra Space Storage, Inc. trades at $150.27 (market cap $30.56B), while Vertex Pharmaceuticals Incorporated trades at $477.12 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays a 4.48% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EXR | VRTX | |
|---|---|---|
Market Cap | $30.56B | $121.09B |
Sector | Real Estate | Health |
52-Week High | $152.75 | $529.59 |
52-Week Low | $126.67 | $366.54 |
Enterprise Value | $44.36B | $115.83B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $148.89, up 2.33% over 24 hours, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.14 exceeding expectations. Revenue reached $3.38B in 2025, with a net income margin of 27.66%, though ROE remains modest at 6.92%. Recent news highlights steady expansion and a $550 million senior notes issuance, while analyst consensus is a $155.88 price target with a mix of Buy and Hold ratings.
Outlook is cautiously optimistic given consistent earnings performance and resilient demand, but risks include high debt levels, competitive pressures, and expense growth outpacing revenue. The stock's valuation metrics like P/E of 32.5 suggest it is priced for growth, yet investor sentiment is divided, with technical indicators showing neutral momentum near key support at $144.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
